Comparable stake leader
Branham Justin Earl
SEC ownership of LISATA THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000320017.
Disclosed value leader
Erkki Ruoslahti
Comparable rows
36/47
Latest evidence
21 Aug 2026
- Public ticker
- LSTA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Branham Justin Earl
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
36 of 47
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Branham Justin Earl
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000320017
- Issuer location
- Basking Ridge, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LISATA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Branham Justin Earl
Disclosed value leader
Erkki Ruoslahti
Comparable rows
36/47
Latest evidence
21 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 5.1%
11 rows are not safely comparable across share classes.
13D/G row: Branham Justin Earl
Showing 1-8 of 47 holder rows.
Quick read
Branham Justin Earl leads the comparable SEC ownership view at 5.1%.
36 of 47 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Branham Justin Earl's linked filing trail.
Comparable ownership
Top 5
Branham Justin Earl
5.1%
Mohammad Azab
1.2%
Steven M. Klosk
1.1%
Gregory B. Brown
1.1%
Cynthia Louise Flowers
1.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 47 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Branham Justin Earl |
13D/G
|
5.1%
|
$536,092
462,149 shares
|
$0 | 21 Aug 2026 |
| Mohammad Azab |
3/4/5
Director
|
1.2%
|
$246,573
104,925 shares
|
— | 09 Jan 2026 |
| Steven M. Klosk |
3/4/5
Director
|
1.1%
|
$225,165
95,815 shares
|
— | 09 Jan 2026 |
| Gregory B. Brown |
3/4/5
Director
|
1.1%
|
$224,798
95,659 shares
|
— | 09 Jan 2026 |
| Cynthia Louise Flowers |
3/4/5
Director
|
1.1%
|
$224,298
95,446 shares
|
— | 09 Jan 2026 |
| Heidi Henson |
3/4/5
Director
|
0.95%
|
$201,453
85,725 shares
|
— | 09 Jan 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.1%
|
$948,046
278,837 shares
|
— | 30 Jun 2026 |
| Yakira Capital Management, Inc. |
13F
Company
|
1.5%
|
$471,107
138,561 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to LISATA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Erkki Ruoslahti
Net 12M change
$0
Latest report
09 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Erkki Ruoslahti | Director | $3,561,521 | Mixed | 09 Jan 2023 | ||
| Steven S. Myers | Director | $668,142 | Mixed | 10 Jan 2022 | ||
| Michael H. Davidson | Director | $627,161 | Mixed | 10 Jan 2022 | ||
| David J. Mazzo | President & CEO, Director | $614,423 | Mixed | 09 Jan 2026 | ||
| Anne Clem Whitaker | Director | $546,079 | Mixed | 10 Jan 2022 | ||
| Todd C. Girolamo | CLO, SVP of Corp Dev | $480,873 | Mixed | 13 Jan 2022 | ||
| Peter G. Traber | Director | $446,078 | Mixed | 10 Jan 2022 | ||
| Mohammad Azab | Director | $246,573 | Mixed | 09 Jan 2026 | ||
| Steven M. Klosk | Director | $225,165 | Mixed | 09 Jan 2026 | ||
| Gregory B. Brown | Director | $224,798 | Mixed | 09 Jan 2026 | ||
| Cynthia Louise Flowers | Director | $224,298 | Mixed | 09 Jan 2026 | ||
| Heidi Henson | Director | $201,453 | Mixed | 09 Jan 2026 | ||
| Kristen K. Buck | EVP, R&D and CMO | $184,120 | Mixed | 09 Jan 2026 | ||
| Tariq Imam | SVP, Bus Dev, General Counsel | $71,073 | Mixed | 09 Jan 2026 | ||
| James Nisco | SVP, Fin/Treas, Chief Actg Off | $63,652 | Mixed | 09 Jan 2026 | ||
| David W. Slack | President & CBO, Director | $61,720 | Mixed | 09 Jan 2023 |
Recent insider transactions for LISATA THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David J. Mazzo | LSTA | Common Stock | Tax liability | -11.6% | -41,096 | 311,890 | 09 Jan 2026 | Direct | ||
| David J. Mazzo | LSTA | Common Stock | Award | 29.8% | 81,000 | 352,986 | 09 Jan 2026 | Direct | ||
| David J. Mazzo | LSTA | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 09 Jan 2026 | Direct | |||
| James Nisco | LSTA | Common Stock | Tax liability | -16.1% | -6,180 | 32,311 | 09 Jan 2026 | Direct | ||
| James Nisco | LSTA | Common Stock | Award | 63.8% | 15,000 | 38,491 | 09 Jan 2026 | Direct | ||
| James Nisco | LSTA | Stock Option (Right to Buy) | Award | 7,000 | 7,000 | 09 Jan 2026 | Direct | |||
| Tariq Imam | LSTA | Common Stock | Tax liability | -8.85% | -3,501 | 36,078 | 09 Jan 2026 | Direct | ||
| Tariq Imam | LSTA | Common Stock | Award | 61% | 15,000 | 39,579 | 09 Jan 2026 | Direct | ||
| Tariq Imam | LSTA | Stock Option (Right to Buy) | Award | 7,000 | 7,000 | 09 Jan 2026 | Direct | |||
| Kristen K. Buck | LSTA | Common Stock | Tax liability | -10.8% | -11,332 | 93,462 | 09 Jan 2026 | Direct | ||
| Kristen K. Buck | LSTA | Common Stock | Award | 31.3% | 25,000 | 104,794 | 09 Jan 2026 | Direct | ||
| Kristen K. Buck | LSTA | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 09 Jan 2026 | Direct | |||
| Steven M. Klosk | LSTA | Common Stock | Award | 46.6% | 30,456 | 95,815 | 09 Jan 2026 | Direct | ||
| Heidi Henson | LSTA | Common Stock | Award | 55.1% | 30,456 | 85,725 | 09 Jan 2026 | Direct | ||
| Cynthia Louise Flowers | LSTA | Common Stock | Award | 46.9% | 30,456 | 95,446 | 09 Jan 2026 | Direct | ||
| Gregory B. Brown | LSTA | Common Stock | Award | 46.7% | 30,456 | 95,659 | 09 Jan 2026 | Direct | ||
| Mohammad Azab | LSTA | Common Stock | Award | 40.9% | 30,456 | 104,925 | 09 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.